双歧杆菌四联活菌联合头孢噻肟钠对肝硬化并发自发性腹膜炎患者的临床疗效及安全评估

Clinical efficacy and safety evaluation of bifidobacterium quadruplet combined with cefotaxime sodium in the treatment of patients with cirrhosis with spontaneous peritonitis

目的:探究双歧杆菌的四联活菌联合头孢噻肟钠治疗肝硬化并发自发性腹膜炎的临床疗效及安全性。方法:2017年5月-2019年5月收治肝硬化并发自发性腹膜炎患者80例,随机分为两组,各40例。对照组给予头孢噻肟钠治疗;观察组采取头孢噻肟钠+双歧杆菌四联活菌治疗。比较两组临床疗效及不良反应发生率。结果:观察组治疗总有效率高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌四联活菌联合头孢噻肟钠治疗肝硬化合并自发性腹膜炎疗效确切。

Objective:To explore the clinical efficacy and safety of bifidobacterium quadruplet combined with cefotaxime sodium in the treatment of cirrhosis with spontaneous peritonitis.Methods:From May 2017 to May 2019,80 patients with cirrhosis with spontaneous peritonitis were enrolled,they were randomly divided into two groups with 40 cases in each group.The control group was treated with cefotaxime sodium and the observation group was treated with cefotaxime sodium+bifidobacterium quadruplet.The clinical efficacy and incidence of adverse reactions between the two groups were compared.Results:The total effective rate of the observation group was higher than the control group,the difference was statistically significant(P<0.05).The adverse reaction rates between the two groups was compared,the difference was not statistically significant(P>0.05).Conclusion:Bifidobacterium quadruplet combined with cefotaxime sodium is effective in treating cirrhosis with spontaneous peritonitis.